Revvity reported that revenue for Q3 2025 was $699 million, an increase from $684 million in the same period a year ago, and GAAP operating income from continuing operations was $82 million with an operating profit margin of 11.7%, compared to $98 million with a margin of 14.3% in the same period a year ago.

1. 01

   Revvity reported that revenue for Q3 2025 was $699 million, an increase from $684 million in the same period a year ago, and GAAP operating income from continuing operations was $82 million with an operating profit margin of 11.7%, compared to $98 million with a margin of 14.3% in the same period a year ago.

2. 02

   The company reported GAAP earnings per share for Q3 2025 of $0.40, compared to $0.77 in the same period a year ago, and adjusted earnings per share from continuing operations of $1.18, compared to $1.28 in the same period a year ago.

3. 03

   Revvity said that for Q3 2025, Life Sciences revenue was $343 million with organic revenue flat and an adjusted operating profit margin of 29.5%, and Diagnostics revenue was $356 million with organic revenue growth of 2% and an adjusted operating profit margin of 25.1%.

4. 04

   The company updated its full-year revenue guidance to $2.83 to $2.88 billion and reaffirmed its organic growth guidance of 2% to 4%, while raising its adjusted EPS guidance to $4.90 to $5.00. The Board of Directors authorized a new 2-year $1 billion share repurchase program.

Analysis scope · Filing body and confirmed press-release exhibitWe analyzed the filing body and confirmed exhibits. This is not a review of other exhibits, investor presentations or the full earnings call.

AI summarized the filing and translated the summary into English; it may differ from the original. For reference only, not investment advice. AI translated the published Korean report into English. Figures are copied as filed, not recalculated.

Original filing

The filing as submitted to SEC EDGAR. You can check the figures and statements of this summary against it.